coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Company profile
Ticker
CHRS
Exchange
Website
CEO
Dennis Lanfear
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioGenerics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Surface Oncology, LLC ...
CHRS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
13 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
4 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
5 Feb 24
8-K
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
22 Jan 24
Transcripts
CHRS
Earnings call transcript
2023 Q4
13 Mar 24
CHRS
Earnings call transcript
2023 Q3
6 Nov 23
CHRS
Earnings call transcript
2023 Q2
2 Aug 23
CHRS
Earnings call transcript
2023 Q1
8 May 23
CHRS
Earnings call transcript
2022 Q4
6 Mar 23
CHRS
Earnings call transcript
2022 Q3
8 Nov 22
CHRS
Earnings call transcript
2022 Q2
7 Aug 22
CHRS
Earnings call transcript
2022 Q1
6 May 22
CHRS
Earnings call transcript
2021 Q4
18 Feb 22
CHRS
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Georgia Erbez
22 Feb 24
3
Georgia Erbez
22 Feb 24
4
Mats Wahlstrom
15 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
ALLIANCEBERNSTEIN L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Mats Wahlstrom
5 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
4
Dennis M Lanfear
23 Jan 24
4
Paul Reider
23 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 80.71 mm | 80.71 mm | 80.71 mm | 80.71 mm | 80.71 mm | 80.71 mm |
Cash burn (monthly) | (no burn) | 17.21 mm | 13.34 mm | 18.12 mm | 18.10 mm | 21.83 mm |
Cash used (since last report) | n/a | 115.28 mm | 89.35 mm | 121.39 mm | 121.23 mm | 146.18 mm |
Cash remaining | n/a | -34.56 mm | -8.64 mm | -40.68 mm | -40.52 mm | -65.47 mm |
Runway (months of cash) | n/a | -2.0 | -0.6 | -2.2 | -2.2 | -3.0 |
Institutional ownership, Q3 2023
85.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 167 |
Opened positions | 39 |
Closed positions | 35 |
Increased positions | 62 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 328.37 bn |
Total shares | 97.48 mm |
Total puts | 342.00 k |
Total calls | 171.80 k |
Total put/call ratio | 2.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 11.65 mm | $43.56 bn |
Vanguard | 9.78 mm | $36.59 bn |
STT State Street | 8.79 mm | $32.88 bn |
Temasek | 7.38 mm | $27.61 bn |
JPM JPMorgan Chase & Co. | 5.38 mm | $20.12 bn |
KKR Group Partnership | 3.95 mm | $116.48 mm |
MS Morgan Stanley | 3.24 mm | $12.13 bn |
Kohlberg Kravis Roberts & Co. | 3.04 mm | $11.35 bn |
Citadel Advisors | 2.66 mm | $9.95 bn |
BCS Barclays | 2.38 mm | $8.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Georgia Erbez | Stock Option Common Stock | Grant | Acquire A | No | No | 2.59 | 54,000 | 139.86 k | 54,000 |
9 Feb 24 | Mats Wahlstrom | Common Stock | Gift | Acquire G | Yes | No | 0 | 99,988 | 0.00 | 99,988 |
9 Feb 24 | Mats Wahlstrom | Common Stock | Gift | Dispose G | No | No | 0 | 99,988 | 0.00 | 0 |
1 Feb 24 | Mats Wahlstrom | Common Stock | Option exercise | Acquire M | No | No | 1.667 | 44,991 | 75.00 k | 99,988 |
1 Feb 24 | Mats Wahlstrom | Common Stock | Option exercise | Acquire M | No | No | 1.667 | 14,997 | 25.00 k | 54,997 |
1 Feb 24 | Mats Wahlstrom | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.667 | 44,991 | 75.00 k | 0 |
1 Feb 24 | Mats Wahlstrom | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.667 | 14,997 | 25.00 k | 0 |
20 Jan 24 | Bryan J McMichael | Common Stock | Payment of exercise | Dispose F | No | No | 2.44 | 1,707 | 4.17 k | 22,972 |
News
Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting
8 Apr 24
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
20 Mar 24
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
14 Mar 24
Recap: Coherus BioSciences Q4 Earnings
13 Mar 24
Coherus BioSciences Q4 2023 Adj EPS $(0.62) Misses $(0.12) Estimate, Sales $91.524M Miss $96.400M Estimate
13 Mar 24
Press releases
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
8 Apr 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
13 Mar 24
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
5 Mar 24
Coherus Completes Divestiture of Ophthalmology Franchise
4 Mar 24
Coherus BioSciences Announces New Employment Inducement Grants
23 Feb 24